Ascendis Pharma A/S
ASND
26 hedge funds and large institutions have $158M invested in Ascendis Pharma A/S in 2015 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 11 increasing their positions, 8 reducing their positions, and 10 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 8
0% more capital invested
Capital invested by funds: $158M → $158M (+$174K)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
21% less funds holding
Funds holding: 33 → 26 (-7)
70% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 10
Top Buyers
| 1 |
VAM
Visium Asset Management
New York
|
+$21.7M |
| 2 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$13.9M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$6.53M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.31M |
| 5 |
AIC
AWM Investment Company
New York
|
+$1.53M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$23.9M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$8.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.5M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.98M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.81M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | -$2.75K | -141 | -77% |
|
|
GPP
27
Great Point Partners
Greenwich,
Connecticut
| – | -$5.5M | -311,222 | Closed |
|
|
SM
28
Sabby Management
Miami Beach,
Florida
| – | -$2.81M | -160,000 | Closed |
|
|
SCM
29
Scopia Capital Management
New York
| – | -$2.6M | -148,114 | Closed |
|
|
HCMT
30
Highland Capital Management (Texas)
Dallas,
Texas
| – | -$1.2M | -67,796 | Closed |
|
31
Millennium Management
New York
| – | -$378K | -21,384 | Closed |
|
|
DM
32
Deerfield Management
New York
| – | -$369K | -20,859 | Closed |
|
|
PI
33
Putnam Investments
Boston,
Massachusetts
| – | -$331K | -18,809 | Closed |
|
|
PA
34
Perceptive Advisors
New York
| – | -$176K | -10,000 | Closed |
|
35
UBS Group
Zurich,
Switzerland
| – | -$14K | -788 | Closed |
|
36
Citigroup
New York
| – | -$1K | -42 | Closed |
|
ASND Hedge Fund Activity: Q3 2015 in Review
26 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q3 2015, worth a combined $158M — up 0.11% from $158M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ASND and 3 opened new positions — a net loss of 7 holders — while 8 trimmed existing stakes and 11 added.
The largest buyer was Visium Asset Management, adding an estimated $21.7M. The largest seller was OrbiMed, cutting an estimated $23.9M.
- 26 institutional investors held Ascendis Pharma A/S (ASND) as of Q3 2015, down from 33 in Q2 2015.
- Funds reported $158M of Ascendis Pharma A/S stock for Q3 2015, up 0.11% quarter-over-quarter.
- 3 funds opened new Ascendis Pharma A/S positions in Q3 2015 and 10 closed out, a net change of -7 holders.
- The largest Ascendis Pharma A/S buyer in Q3 2015 was Visium Asset Management, an estimated $21.7M added.
- The largest Ascendis Pharma A/S seller in Q3 2015 was OrbiMed, an estimated $23.9M sold.
Based on aggregated 13F filings for Q3 2015.